Week 1 calendar for the #RoadToEASCongress2026 Challenge 🔙 Save it, pick the daily prompt, and share your favorite memories from past @EASCongress editions. Day 1⃣ starts tomorrow: Your first EAS Congress — when and where? #EASCongress2026 @eassociety.bsky.social #EASSoMe #CvPrev

🚀 Starting tomorrow: the #RoadToEASCongress2026 Challenge! 14 days of memories, science, community, and excitement on the way to #EASCongress2026. 📅 May 10–23 📍 One prompt per day 💬 Join using #RoadToEASCongress2026 Tag a colleague who should take part! @eassociety.bsky.social #EASSoMe

Lp(a) doesn't just add risk-it reframes it (often a lifelong, family conversation). The question isn't "should we test?" but how we implement testing so results are clear and actionable @lipidjournal.bsky.social 🔗 lipidjournal.com/article/S193... @afgciceromd.bsky.social @eassociety.bsky.social

⏳ Only a few hours to go until the launch of the #GBD2023 at the World Health Summit — and the great news is that you can follow it live on YouTube this afternoon 📽️ 📅 October 12, 2025 — 16:00 CEST / 14:00 UTC 🔗 www.youtube.com/watch?v=qPOi... P.S. All 👀 are on The Lancet today! @ihmeuw.bsky.social

Launch of the Global Burden of Disease Study 2023 | KEY 02

YouTube video by World Health Summit

youtube.com

Happening Today – Don’t Miss It! Join the @eassociety.bsky.social webinar at 17:00 CET to explore the latest Lp(a) guidelines with Dr. Koskinas and Prof. @LaleTokgozoglu. Bring your questions and join the live Q&A—we can’t wait to connect with you online 💫 Rego: eas.to/WebSep29Reg #EASSoMe #CvPrev

Welcome! You are invited to join a webinar: EAS/ESC Guidelines: Lipoprotein(a) – guideline updates and clinical case. After registering, you will receive a confirmation email about joining the webinar...

Join us for an insightful webinar exploring the latest Lipoprotein(a)-related guideline recommendations. The session will feature a 20-minute overview presentation by Dr Konstantinos Koskinas, followe...

eas.to

Feeling honored to be recognized for the 3rd consecutive year on Stanford University and Elsevier’s Top 2% Scientists list. #Grateful to my incredible colleagues and mentors — thank you for your support as we keep pushing boundaries and growing together @unibo.it @eassociety.bsky.social #CvPrev

Super excited to be selected for the first IAS Inflammation Academy 🌟 Looking forward to learning, sharing ideas, and being inspired by amazing mentors and peers #CvPrev #EASSoMe @eassociety.bsky.social 🔗https://athero.org/ias-inflammation-academy/

Detailed results from the pivotal P3 Launch-HTN trial were published today in @jama.com, reinforcing lorundrostat’s efficacy in a real-world setting. Read our press release to learn more: ir.mineralystx.com/news-events/... #BloodPressure #Cardiology #Cardiosky #MLYS

Too many children w/ HeFH go undiagnosed. RCPCH has launched 2 🆓 online modules to help paediatricians & HCPs better spot and support them. Let’s close the gap in care #EASSoMe @eassociety.bsky.social 📚 Learn more & take action 👉 learning.rcpch.ac.uk/courses/mana...

🎤 First time speaking at #RiminiWellness — I shared some insights on non-pharmacological strategies for managing dyslipidemia. Thanks for the invitation and the audience’s practical questions! Science & wellness grow stronger together #RW25 #CvPrev

🚨 Heart disease kills 20M+ yearly. Most prevention? Still stuck in the past. Meet ILEP-SMILE: the 360° strategy tackling not just diet & exercise, but much more! This isn’t a guideline. It’s a global call to action! 🫀🌍 🔗 www.archivesofmedicalscience.com/A-360-Perspe... 🌐 #INPST #PublicHealth

Had the pleasure of delivering a talk at the ANCE Interprovincial Congress on CV prevention & dyslipidemia management in low-risk patients. Empowering 👫 today means healthier tomorrows—for them and the healthcare system. Grateful for the warm welcome! #EASSoMe @eassociety.bsky.social

Great to have Prof. Jung Hyun Choi with us in Bologna during her journey from South Korea to Milan for the ESH Annual Congress. A meaningful exchange ahead of #ESH2025 — and a perfect occasion to let her try tagliatelle al ragù! 🇮🇹🍝 @afgciceromd.bsky.social @unibo.bsky.social

Novel staging system for systemic metabolic disorders! With actionable treatment

Federica Fogacci@federicafogacci.bsky.social · last yr.

The brand-new EAS Consensus is here—offering a game-changing, clinically actionable roadmap to tackle met disorders linked to obesity. Time to move from treating symptoms to a full-body, root-cause approach @eassociety.bsky.social @cibiocm.bsky.social #EASSoMe

Step zero before lifestyle changes, meds, or surgery? Read the 🆕 EAS Consensus! 🔗https://doi.org/10.1093/eurheartj/ehaf314 Because being clueless isn’t a treatment strategy 😎 #EASSoMe @eassociety.bsky.social @cibiocm.bsky.social

Federica Fogacci@federicafogacci.bsky.social · last yr.

How do we act? 1⃣ Start w/ lifestyle changes—always the foundation 2⃣ Add the right medications when needed 3⃣ In severe cases, consider surgery It’s not one-size-fits-all: treatment must match the stage and the organs involved #EASSoMe @eassociety.bsky.social

The brand-new EAS Consensus is here—offering a game-changing, clinically actionable roadmap to tackle met disorders linked to obesity. Time to move from treating symptoms to a full-body, root-cause approach @eassociety.bsky.social @cibiocm.bsky.social #EASSoMe

#MyEAS2025 The live discussion of my case on statin intolerance at #EASCongress2025 was truly exciting! The EAS Stage was packed—much more than the photo shows—and the audience was incredibly engaged. Big thanks to everyone who joined for this rewarding discussion! @eassociety.bsky.social

#MyEAS2025 Honored to join as a panelist at #EASCongress2025 in a session on the power of SoMe in science & networking. Sharing how these platforms launched my journey into ath was truly exciting—and I hope it inspires other early-career researchers! @eassociety.bsky.social @katioorni.bsky.social

💡 Key takeaway in one line! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social Excited to share the latest breakthroughs in lipid research and clinical practice. Here’s a quick snapshot of yesterday's late-breaking findings 👇

The BROADWAY study results are out now in @nejm.org, published simultaneously with their presentation at #EASCongress2025 🙌 So if you missed Prof. Nicholls' talk—you can catch up here www.nejm.org/doi/full/10.... #EASCongress2025 #MyEAS2025 @maciejbanach.bsky.social @eassociety.bsky.social

Federica Fogacci@federicafogacci.bsky.social · last yr.

BROADWAY study: Obicetrapib, added to maximally tolerated LLT in high-risk CV patients, reduced placebo-adjusted LDL-C by 32.6% at day 84 and 24% at day 365, with 51% of patients reaching LDL-C <55 mg/dL #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

Obicetrapib was well tolerated in the BROADWAY study. Long-term effects on CV outcomes will be evaluated in the ongoing PREVAIL trial—but current results suggest it holds considerable promise for improving lipid control in high CV risk patients #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

BROADWAY Study: Additionally, obicetrapib led to a placebo-adj 33.5% reduction in Lp(a), independent of its effects on other lipid parameters and HDL-C increase. The broader lipid effects are also very encouraging #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

Federica Fogacci@federicafogacci.bsky.social · last yr.

BROADWAY study: Obicetrapib, added to maximally tolerated LLT in high-risk CV patients, reduced placebo-adjusted LDL-C by 32.6% at day 84 and 24% at day 365, with 51% of patients reaching LDL-C <55 mg/dL #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

BROADWAY study: Obicetrapib, added to maximally tolerated LLT in high-risk CV patients, reduced placebo-adjusted LDL-C by 32.6% at day 84 and 24% at day 365, with 51% of patients reaching LDL-C <55 mg/dL #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

The results of the TANDEM trial have been published in @thelancet.bsky.social , simultaneously with their presentation at the #EASCongress2025! Read the full article here: doi.org/10.1016/S014... @erinmichos.bsky.social @eassociety.bsky.social #MyEAS2025

While the TANDEM trial has limitations—short follow-up, mainly White participants, and no systematic CV event tracking—if approved, the fixed-dose combo could still offer a valuable new oral option for lowering LDL-C in patients on maximally tolerated LLT #EASCongress2025 @eassociety.bsky.social

Federica Fogacci@federicafogacci.bsky.social · last yr.

The TANDEM trial: the fixed-dose combo of obicetrapib + ezetimibe cut LDL-C by nearly 50%, with over 70% of participants reaching levels below 1.4 mmol/L. A promising step forward in lipid lowering! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

Beyond LDL-C, the TANDEM trial showed very encouraging results on ApoB and a high proportion of patients reaching lipid targets. The fixed-dose combo was also well tolerated #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

Federica Fogacci@federicafogacci.bsky.social · last yr.

The TANDEM trial: the fixed-dose combo of obicetrapib + ezetimibe cut LDL-C by nearly 50%, with over 70% of participants reaching levels below 1.4 mmol/L. A promising step forward in lipid lowering! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

The TANDEM trial: the fixed-dose combo of obicetrapib + ezetimibe cut LDL-C by nearly 50%, with over 70% of participants reaching levels below 1.4 mmol/L. A promising step forward in lipid lowering! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

Absolute pleasure to present at #EASCongress2025. Come and find me if you want to talk anything spatial, proteomics or mechanisms of vulnerable plaque! @eassociety.bsky.social

Federica Fogacci@federicafogacci.bsky.social · last yr.

#EASCongress2025 Late Breakers - Key takeaway in one line! #MyEAS2025 Check out the slide below for a one-line summary of each late-breaking presentation — concise, clear, and all in one place 😎 @eassociety.bsky.social

#EASCongress2025 Late Breakers - Key takeaway in one line! #MyEAS2025 Check out the slide below for a one-line summary of each late-breaking presentation — concise, clear, and all in one place 😎 @eassociety.bsky.social

Whether you're attending #EASCongress2025 remotely or in person, get 🛋️ — the Opening Ceremony is about to start! Right after, the Anitschkow Lecture by Prof. Ridker is the perfect way to kick off 4 💥 days of cutting-edge ath research and treatment @EASCongress @society_eas